PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
1.75%
Revenue growth exceeding 1.5x Medical - Pharmaceuticals median of 0.98%. Joel Greenblatt would investigate if growth quality matches quantity.
1.74%
Cost growth exceeding 1.5x Medical - Pharmaceuticals median of 0.67%. Jim Chanos would check for structural cost disadvantages.
1.77%
Growth of 1.77% versus flat Medical - Pharmaceuticals gross profit. Walter Schloss would verify quality.
0.02%
Margin change of 0.02% versus flat Medical - Pharmaceuticals margins. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-16.73%
Other expenses reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
-0.62%
Operating expenses reduction while Medical - Pharmaceuticals median is 0.12%. Seth Klarman would investigate advantages.
1.34%
Total costs growth exceeding 1.5x Medical - Pharmaceuticals median of 0.37%. Jim Chanos would check for waste.
5.88%
Interest expense change of 5.88% versus flat Medical - Pharmaceuticals costs. Walter Schloss would verify control.
5.62%
D&A growth exceeding 1.5x Medical - Pharmaceuticals median of 1.05%. Jim Chanos would check for overinvestment.
-29.55%
EBITDA decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-30.76%
EBITDA margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
15.41%
Operating income growth exceeding 1.5x Medical - Pharmaceuticals median of 1.14%. Joel Greenblatt would investigate advantages.
13.43%
Operating margin growth exceeding 1.5x Medical - Pharmaceuticals median of 0.37%. Joel Greenblatt would investigate advantages.
13.27%
Other expenses growth exceeding 1.5x Medical - Pharmaceuticals median of 2.66%. Jim Chanos would check for issues.
15.20%
Pre-tax income growth exceeding 1.5x Medical - Pharmaceuticals median of 1.04%. Joel Greenblatt would investigate advantages.
13.22%
Margin change of 13.22% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
18.50%
Tax expense change of 18.50% versus flat Medical - Pharmaceuticals. Walter Schloss would verify strategy.
13.61%
Net income growth while Medical - Pharmaceuticals declines. Peter Lynch would examine advantages.
11.65%
Margin change of 11.65% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
13.59%
EPS growth exceeding 1.5x Medical - Pharmaceuticals median of 1.49%. Joel Greenblatt would investigate advantages.
13.59%
Diluted EPS growth exceeding 1.5x Medical - Pharmaceuticals median of 1.49%. Joel Greenblatt would investigate advantages.
0.02%
Share count reduction exceeding 1.5x Medical - Pharmaceuticals median of 0.16%. Joel Greenblatt would investigate strategy.
0.02%
Diluted share reduction exceeding 1.5x Medical - Pharmaceuticals median of 0.22%. Joel Greenblatt would investigate strategy.